Safety Shot President Jordan Schur Invests an Additional $3.4 Million in the Company Through His Family Fund, Core 4 Capital Corp.

Rhea-AI Summary

Safety Shot, Inc. (Nasdaq: SHOT) announced that its President, Jordan Schur, has invested an additional $3.4 million in the company through his family investment group, Core 4 Capital Corp. This investment comes in the form of a private placement, with the issuance of 3,370,787 shares at $0.89 per share and 3,370,767 warrants at $0.125 per warrant. Combined with previous investments, Core 4 has now invested a total of $9.4 million in Safety Shot.

Schur expressed enthusiasm about the company's progress, citing recent clinical trial results that demonstrate Safety Shot's effectiveness in lowering Blood Alcohol Content and alleviating hangover symptoms. The company plans to use the proceeds for working capital, general corporate purposes, and to support the growth of the Safety Shot brand.

Positive

• Additional $3.4 million investment from company President Jordan Schur
• Total investment from Core 4 Capital Corp. reaches $9.4 million
• Clinical trial proves product's effectiveness in lowering Blood Alcohol Content
• Funds to be used for working capital and brand growth

Negative

• None.

Insights

Financial Analyst

This $3.4 million investment from Safety Shot's President is a strong vote of confidence in the company's future. The total investment of $9.4 million from Core 4 Capital Corp. demonstrates significant insider commitment. The share price of $0.89 and warrant price of $0.125 provide interesting data points for valuation. However, this dilutive offering at a relatively low price might concern existing shareholders. The funds will bolster the company's working capital, which is important for growth-stage companies. The clinical trial results mentioned could be a game-changer if they translate to market success, but investors should closely monitor upcoming financial reports to gauge the impact on revenue and profitability.

Medical Research Analyst

The clinical trial results from the Center for Applied Health Sciences are intriguing. Safety Shot's product demonstrating the ability to lower Blood Alcohol Content and alleviate hangover symptoms could be groundbreaking in the health and wellness sector. However, it's important to see the full study details, including sample size, methodology and statistical significance. The metabolism support claim needs further explanation and peer review. If these results hold up under scrutiny, Safety Shot could potentially disrupt the alcohol consumption market. Investors should watch for FDA reactions, potential partnerships with alcohol brands and consumer adoption rates to gauge the product's true market potential.

Market Research Analyst

Safety Shot's product sits at an interesting intersection of health, wellness and the alcohol industry. The market for hangover remedies and alcohol-related health products is growing, but it's also crowded and skeptical. The clinical trial results could be a key differentiator if marketed effectively. The $9.4 million total investment suggests a significant marketing and distribution push may be coming. Investors should watch for the go-to-market strategy, including target demographics, pricing and distribution channels. The company's ability to navigate regulatory challenges and build consumer trust will be crucial. Early adoption rates and repeat purchase data will be key indicators of product viability and long-term growth potential.

JUPITER, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company” or “Safety Shot”) is pleased to announce that Safety Shot President Jordan Schur has invested in a $3.4 million private placement in the Company through his family investment group, Core 4 Capital Corp. (“Core 4”).

In addition to gross proceeds of $5 million that were raised in April and $1 million in June from Core 4, Safety Shot just raised an additional $3.4 million from the issuance of 3,370,787 Shares at a price of $0.89 and 3,370,767 warrants at $0.125 per warrant, With this investment, Core 4 has made a combined investment of $9.4 million from Core 4.

“I have seen amazing progress in this Company since I joined approximately six months ago,” said Schur. “The recent release of our clinical trial conducted by the Center for Applied Health Sciences shows that our product is clinically proven to lower Blood Alcohol Content by supporting its metabolism and alleviates the next morning symptoms of excessive drinking. I couldn’t be more excited about the Company’s future,” continued Schur.

The Company intends to use the net proceeds from the Offering as working capital, towards general corporate purposes, and to fund the continued development and growth of the Safety Shot brand. For more details of the investment, please see the Company’s Current Report on Form 8-k to be filed on September 4, 2024.

About Safety Shot, Inc.

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy, and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot’s ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot’s future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market safely.

Connect with Safety Shot: Website: www.DrinkSafetyShot.com Twitter: @SafetyShotInc Instagram: @SafetyShotInc Facebook: Safety Shot, Inc.

Media and Investor Contact:

Autumn Communications
Jessica Weinberger
Phone: 916-677-7495
Email: shot@autumncommunications.com

Medon Michaelides
Investor Relations
Phone: 561-244-7100
Email: investors@drinksafetyshot.com

FAQ

How much did Safety Shot (SHOT) raise in its recent private placement?

Safety Shot (SHOT) raised $3.4 million in its recent private placement from Core 4 Capital Corp., the family investment group of President Jordan Schur.

What was the share price for Safety Shot's (SHOT) recent private placement on September 4, 2024?

The share price for Safety Shot's (SHOT) recent private placement was $0.89 per share, with 3,370,787 shares issued.

What did Safety Shot's (SHOT) clinical trial results show?

Safety Shot's (SHOT) clinical trial results showed that their product is clinically proven to lower Blood Alcohol Content by supporting its metabolism and alleviates the next morning symptoms of excessive drinking.

How much has Core 4 Capital Corp. invested in total in Safety Shot (SHOT)?

Core 4 Capital Corp. has invested a total of $9.4 million in Safety Shot (SHOT), including the recent $3.4 million private placement.